New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections

Overview

Journal Chem Asian J

Specialty Chemistry

Date 2019 Aug 8

PMID 31389664

Citations 93

Authors

Erik De Clercq

Affiliations

Soon will be listed here.

Abstract

Eight different compounds, all nucleoside analogues, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections. They can be considered as either (i) adenine analogues (3-deazaneplanocin A, galidesivir, GS-6620 and remdesivir) or (ii) guanine analogues containing the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir). All eight owe their mechanism of action to hydrogen bonded base pairing with either (i) uracil or (ii) cytosine. Four out of the eight compounds (galidesivir, GS-6620, remdesivir and pyrazofurin) are C-nucleosides, and two of them (GS-6620, remdesivir) also contain a phosphoramidate part. The C-nucleoside and phosphoramidate (and for the adenine analogues the 1'-cyano group as well) may be considered as essential attributes for their antiviral activity.

Citing Articles

Advancements in the development of antivirals against SARS-Coronavirus.

Kumar M, Baig M, Bhardwaj K Front Cell Infect Microbiol. 2025; 15:1520811.

PMID: 39917633 PMC: 11798951. DOI: 10.3389/fcimb.2025.1520811.

Innovative anti-proliferative effect of the antiviral favipiravir against MCF-7 breast cancer cells using green nanoemulsion and eco-friendly assessment tools.

Abd-Elrasheed E, Fahim S, Nessim C, El-Helaly S Sci Rep. 2024; 14(1):27939.

PMID: 39537766 PMC: 11561084. DOI: 10.1038/s41598-024-78422-2.

Metabolic RNA labeling in non-engineered cells following spontaneous uptake of fluorescent nucleoside phosphate analogues.

Pfeiffer P, Nilsson J, Gallud A, Baladi T, Le H, Bood M Nucleic Acids Res. 2024; 52(17):10102-10118.

PMID: 39162218 PMC: 11417403. DOI: 10.1093/nar/gkae722.

Immunization against Medically Important Human Coronaviruses of Public Health Concern.

Nimer N, Nimer S Can J Infect Dis Med Microbiol. 2024; 2024:9952803.

PMID: 38938549 PMC: 11208815. DOI: 10.1155/2024/9952803.

POxload: Machine Learning Estimates Drug Loadings of Polymeric Micelles.

Kehrein J, Bunker A, Luxenhofer R Mol Pharm. 2024; 21(7):3356-3374.

PMID: 38805643 PMC: 11394009. DOI: 10.1021/acs.molpharmaceut.4c00086.

References

Gowen B, Wong M, Jung K, Sanders A, Mendenhall M, Bailey K . In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007; 51(9):3168-76. PMC: 2043187. DOI: 10.1128/AAC.00356-07. View

Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A . Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 2015; 213(8):1253-61. PMC: 4799667. DOI: 10.1093/infdis/jiv586. View

Crotty S, Maag D, Arnold J, Zhong W, Lau J, Hong Z . The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000; 6(12):1375-9. DOI: 10.1038/82191. View

Safronetz D, Rosenke K, Westover J, Martellaro C, Okumura A, Furuta Y . The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep. 2015; 5:14775. PMC: 4600983. DOI: 10.1038/srep14775. View

Morrey J, Taro B, Siddharthan V, Wang H, Smee D, Christensen A . Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 2008; 80(3):377-9. PMC: 2587511. DOI: 10.1016/j.antiviral.2008.07.009. View

Delang L, Abdelnabi R, Neyts J . Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153:85-94. DOI: 10.1016/j.antiviral.2018.03.003. View

Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S . Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis. 2014; 8(5):e2804. PMC: 4006714. DOI: 10.1371/journal.pntd.0002804. View

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K . Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005; 49(3):981-6. PMC: 549233. DOI: 10.1128/AAC.49.3.981-986.2005. View

De Clercq E . New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019; 14(22):3962-3968. PMC: 7159701. DOI: 10.1002/asia.201900841. View

10.

De Clercq E, Cools M, Balzarini J, Marquez V, Borcherding D, Borchardt R . Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob Agents Chemother. 1989; 33(8):1291-7. PMC: 172642. DOI: 10.1128/AAC.33.8.1291. View

11.

De Clercq E . C-Nucleosides To Be Revisited. J Med Chem. 2015; 59(6):2301-11. DOI: 10.1021/acs.jmedchem.5b01157. View

12.

Julander J, Smee D, Morrey J, Furuta Y . Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res. 2009; 82(3):169-71. PMC: 2704019. DOI: 10.1016/j.antiviral.2009.02.201. View

13.

Smither S, Eastaugh L, Steward J, Nelson M, Lenk R, Lever M . Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014; 104:153-5. DOI: 10.1016/j.antiviral.2014.01.012. View

14.

Bai C, Mu J, Kargbo D, Song Y, Niu W, Nie W . Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016; 63(10):1288-1294. DOI: 10.1093/cid/ciw571. View

15.

Eriksson B, Helgstrand E, Johansson N, Larsson A, MISIORNY A, Noren J . Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 1977; 11(6):946-51. PMC: 352108. DOI: 10.1128/AAC.11.6.946. View

16.

Balzarini J, Karlsson A, Wang L, Bohman C, Horska K, Votruba I . Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem. 1993; 268(33):24591-8. View

17.

Bray M, Raymond J, Geisbert T, Baker R . 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 2002; 55(1):151-9. DOI: 10.1016/s0166-3542(02)00018-9. View

18.

De Clercq E . Dancing with chemical formulae of antivirals: a personal account. Biochem Pharmacol. 2013; 86(6):711-25. DOI: 10.1016/j.bcp.2013.07.012. View

19.

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

20.

Murakami E, Wang T, Babusis D, Lepist E, Sauer D, Park Y . Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620. Antimicrob Agents Chemother. 2014; 58(4):1943-51. PMC: 4023801. DOI: 10.1128/AAC.02350-13. View